Enhanced antinociception of the model opioid peptide [D- Penicillamine2,5] enkephalin by P-glycoprotein modulation

Pharmaceutical Research

Volumn 16, Issue 2, 1999, Pages 296-301

  Chen, Cuiping ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Antinociception; Blood brain barrier; Opioids; P glycoprotein; D Penicillamine2,5 enkephalin

Indexed keywords

ACRIDONE DERIVATIVE; DELTA OPIATE RECEPTOR; ELACRIDAR; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GLYCOPROTEIN P; N [4 [2 (1,2,3,4 TETRAHYDRO 6,7 DIMETHOXY 2 ISOQUINOLINYL)ETHYL]PHENYL] 9,10 DIHYDRO 5 METHOXY 9 OXO 5 ACRIDINE CARBOXAMIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033051513     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018892811980     Document Type: Article

References (26)

1. 1. H. I. Mosberg, R. Hurst, V. J. Hruby, K. Gee, H. I. Yamamura, J. J. Galligan, and T. F. Burks. Bis-penicillamine possesses highly improved specificity toward delta opioid receptors. Natl. Acad. Sci. U.S.A. 80:5871-5874 (1983).
2. 2,5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66:1289-1299 (1996).
3. 5]-enkephalin and two halogenated analogs after intravenous administration J. Pharmacol. Exp. Ther. 259:1109-1117 (1991).
4. 5]enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. J. Pharmacol. Exp. Ther. 263:1308-1316 (1992).
5. 5]enkephalin opioid analogs. J. Pharmacol. Exp. Ther. 266:1649-1655 (1993).
6. 2,5]enkephalin in rats. J. Chromatogr. Biomed. Appl. 681:363-373 (1996).
7. 2,5]enkephalin in rats. Pharm. Res. 14:345-350 (1997).
8. 8. M. V. Shah, K. L. Audus, and R. T. Borchardt. The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through blood-brain barrier Pharm. Res. 6:624-627 (1989).
9. 2.5]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 283:1151-1159 (1997).
10. 10. C. F. Higgins. ABC transporters: from microorganisms to man. Ann. Rev. Cell. Biol. 67-113 (1992).
11. 11. M. M. Gottesman and I. Pastan. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263:12163-12166 (1989).
12. 12. B. L. Lum, M. P. Gosland, S. Kaubisch, and B. I. Sikic. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacother. 13:88-109 (1993).
13. 13. B. L. Lum and M. P. Gosland. MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol.-Oncol. Clinics North America 9:319-336 (1995).
14. 14. R. C. Sharma, S. Inoue, J. Roitelman, R. T. Schimke, and R. D. Simoni. Peptide transport by the multidrug resistance pump. J. Biol. Chem. 267:5731-5734 (1992).
15. 15. T. Saeki, K. Ueda, Y. Tanigawana, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268:6077-6080 (1993).
16. 16. A. H. Schinkel, E. Wagenaar, C. A. A. M. Mol, and L. Van Deemter. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:2517-2524 (1996).
17. 17. R. Callaghan and J. R. Riordan. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 268:16059-16064 (1993).
18. 2,5]enkephalin in the mdrla gene-deficient mice. J. Pharmacol. Exp. Ther. 287:545-552 (1998).
19. 19. S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L. R. Brouwer. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 15:599-605 (1998).
20. 20. J. M. Ford and W. N. Hait. Pharmacology of drug that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199 (1990).
21. 21. M. V. Relling. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther. Drug Monitor. 18:350-356 (1996).
22. 22. I. Pastan and M. M. Gottesman. Multidrug resistance. Ann. Rev. Med. 42:277-286 (1991).
23. 23. B. Dumaitre and N. Dodic. Patent Application WO 92/12132 (1992).
24. 24. F. Hyafil, C. Vergely, P. D. Vignaud, and T. Grand-Perret. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53:4595-4602 (1994).
25. 25. G. D. Pennock, W. S. Dalton, W. R. Roeske, C. P. Appleton, K. Mosley, P. Plezia, T. P. Miller, and S. E. Salmon. Systemic toxic effects associated with high-dose of verapamil infusion and chemotherapy administration. J. Natl. Cancer Inst. 83:105-110 (1991).
26. 26. H. H. Loh, L. F. Tseng, E. Wei, and C. H. Li. Beta-endorphin is a potent analgesic agent. Proc. Natl. Acad. Sci. U.S.A. 73:2895-2898 (1976).